Clinical Trials Browser

Phase 1/2 × Solid Tumor × atezolizumab × Clear all

NCT02541604 2020-02-25

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors

Phase 1/2 Terminated

87 enrolled 41 charts

Other solid neoplasm

Solid Tumor